Open in Screener

PBYI

Puma Biotechnology Inc

Jun 15 • 04:00PM ET

7.07

-0.26 -3.55 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: NKTR KROS INCY VKTX BMRN KRYS RYTM AXSM MDGL NBIX

| Held by: AVUV VTI IWM VXF IWN VTWO BSVO FESM DFAT DFAS

Index	RUT	P/E	14.81	EPS (ttm)	0.48	Insider Own	23.49%	Shs Outstand	50.88M	Perf Week	3.21%
Market Cap	359.86M	Forward P/E	35.35	EPS next Y	0.20	Insider Trans	-1.11%	Shs Float	38.94M	Perf Month	-1.67%
Enterprise Value	272.17M	PEG	-	EPS next Q	0.04	Inst Own	66.69%	Short Float	9.77%	Perf Quarter	16.47%
Income	24.38M	P/S	1.58	EPS this Y	-52.46%	Inst Trans	6.38%	Short Ratio	14.67	Perf Half Y	23.39%
Sales	227.18M	P/B	2.80	EPS next Y	-31.03%	ROA	12.54%	Short Interest	3.80M	Perf YTD	18.82%
Book/sh	2.52	P/C	3.47	EPS next 5Y	-	ROE	21.62%	52W High	7.90 -10.49%	Perf Year	111.04%
Cash/sh	2.04	P/FCF	6.71	EPS past 3/5Y	- -	ROIC	18.34%	52W Low	3.03 133.33%	Perf 3Y	99.15%
Dividend Est.	-	EV/EBITDA	6.78	Sales past 3/5Y	0.05% 0.29%	Gross Margin	74.46%	Volatility	4.49% 3.76%	Perf 5Y	-33.18%
Dividend TTM	-	EV/Sales	1.20	EPS Y/Y TTM	-37.13%	Oper. Margin	12.98%	ATR (14)	0.29	Perf 10Y	-78.07%
Dividend Ex-Date	-	Quick Ratio	2.24	Sales Y/Y TTM	-2.38%	Profit Margin	10.73%	RSI (14)	48.88	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.38	EPS Q/Q	-223.83%	SMA20	0.12%	Beta	1.20	Target Price	5.00
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	-2.59%	SMA50	-2.52%	Rel Volume	0.68	Prev Close	7.33
Employees	179	LT Debt/Eq	0.04	Earnings	May 07 AMC	SMA200	16.01%	Avg Volume	259.32K	Price	7.07
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	58.82% 6.67%	Trades		Volume	177,367	Change	-3.55%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Jun-03-26 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-08-26 08:30AM	Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 05:37PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press)
04:05PM	Puma Biotechnology Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:15PM	Loading…
Apr-23-26 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results (Business Wire)
Apr-02-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-26 12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks) -25.00%
08:30AM	Puma Biotechnology, Inc. Q4 2025 Earnings Call Summary (Moby)
01:12AM	Puma Biotechnology Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-26 06:45PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:15PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 07:30PM	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks) +5.34%
04:15PM	Loading…
Feb-23-26 04:15PM	Puma Biotechnology to Present at TD Cowens 46th Annual Health Care Conference (Business Wire)
Feb-12-26 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-10-26 05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-07-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 11:20AM	Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? (Barchart)
Dec-22-25 04:10PM	Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) (Business Wire)
Dec-17-25 11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Dec-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.57%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-07-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +22.24% -21.04%
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
12:03AM	Puma Biotechnology Inc (PBYI) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Royalty ... (GuruFocus.com)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
04:55PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Puma Biotechnology Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-23-25 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire)
Oct-09-25 05:06AM	CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Oct-02-25 05:21PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-17-25 02:27PM	What Do Analysts Think About Puma Biotechnology (PBYI)? (Insider Monkey)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
Sep-04-25 05:25PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-01-25 09:55AM	Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-28-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.83%
Aug-12-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
09:15AM	Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:11AM	Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT (Insider Monkey)
Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16% +31.44%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

FounderMr. Alan H. Auerbach

CFO & Principal Accounting OfficerMr. Maximo F. Nougues

FRAPSMr. Douglas Hunt B.Sc.

Chief Accounting OfficerMr. Gordon G. Esplin

Senior Director of Investor RelationsMr. Mariann Ohanesian

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON TROY EDWARD	Director	Jun 12 '26	Sale	7.20	10,800	77,748	59,750	Jun 15 08:16 PM
Stuglik Brian M	Director	Jun 12 '26	Sale	7.20	8,100	58,311	113,858	Jun 15 08:14 PM
Senderowicz Adrian	Director	Jun 12 '26	Sale	7.20	27,000	194,311	27,000	Jun 15 08:13 PM
MOYES JAY M	Director	Jun 12 '26	Sale	7.22	22,000	158,796	58,322	Jun 15 08:10 PM
Dorval Allison	Director	Jun 12 '26	Sale	7.20	11,610	83,579	90,780	Jun 15 08:09 PM
Senderowicz Adrian	Director	Jun 12 '26	Proposed Sale	7.26	27,000	196,020		Jun 12 10:39 AM
MOYES JAY M	Director	Jun 12 '26	Proposed Sale	7.26	22,000	159,720		Jun 12 10:37 AM
Dorval Allison	Director	Jun 12 '26	Proposed Sale	7.26	11,610	84,289		Jun 12 10:33 AM
Stuglik Brian M	Director	Jun 12 '26	Proposed Sale	7.26	8,100	58,806		Jun 12 10:23 AM
WILSON TROY EDWARD	Director	Jun 12 '26	Proposed Sale	7.26	10,800	78,408		Jun 12 09:58 AM
AUERBACH ALAN H	President and CEO	Jan 07 '26	Sale	5.88	18,012	105,893	7,145,951	Jan 08 08:27 PM
AUERBACH ALAN H	President and CEO	Jan 06 '26	Sale	5.84	16,938	98,986	7,163,963	Jan 08 08:27 PM
HUNT DOUGLAS M	See Remarks	Jan 07 '26	Sale	5.88	5,014	29,477	155,907	Jan 08 08:15 PM
HUNT DOUGLAS M	See Remarks	Jan 06 '26	Sale	5.84	3,973	23,218	160,921	Jan 08 08:15 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 07 '26	Sale	5.88	6,405	37,655	193,284	Jan 08 08:14 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 06 '26	Sale	5.84	4,540	26,532	199,689	Jan 08 08:14 PM
AUERBACH ALAN H	Officer	Jan 07 '26	Proposed Sale	5.88	18,012	105,893		Jan 07 04:28 PM
HUNT DOUGLAS M	Officer	Jan 07 '26	Proposed Sale	5.88	5,014	29,477		Jan 07 04:25 PM
NOUGUES MAXIMO F	Officer	Jan 07 '26	Proposed Sale	5.88	6,405	37,655		Jan 07 04:24 PM
NOUGUES MAXIMO F	Officer	Jan 06 '26	Proposed Sale	5.84	4,540	26,530		Jan 06 04:53 PM
HUNT DOUGLAS M	Officer	Jan 06 '26	Proposed Sale	5.84	3,973	23,217		Jan 06 04:45 PM
AUERBACH ALAN H	Officer	Jan 06 '26	Proposed Sale	5.84	16,938	98,979		Jan 06 04:44 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Sale	4.86	20,000	97,228	54,000	Nov 13 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Proposed Sale	4.86	20,000	97,228		Nov 12 08:29 AM
Cesano Alessandra	Director	Jul 18 '25	Sale	3.37	27,000	90,909	41,850	Jul 22 07:51 PM
Cesano Alessandra	Director	Jul 18 '25	Proposed Sale	3.37	27,000	90,909		Jul 18 04:16 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 08 '25	Sale	3.53	5,587	19,739	208,164	Jul 10 08:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 09 '25	Sale	3.54	3,935	13,910	204,229	Jul 10 08:56 PM
HUNT DOUGLAS M	See Remarks	Jul 08 '25	Sale	3.53	4,374	15,453	168,337	Jul 10 08:52 PM
HUNT DOUGLAS M	See Remarks	Jul 09 '25	Sale	3.54	3,443	12,171	164,894	Jul 10 08:52 PM
AUERBACH ALAN H	President and CEO	Jul 08 '25	Sale	3.53	25,592	90,417	7,202,481	Jul 10 08:49 PM
AUERBACH ALAN H	President and CEO	Jul 09 '25	Sale	3.54	21,580	76,285	7,180,901	Jul 10 08:49 PM
NOUGUES MAXIMO F	Officer	Jul 09 '25	Proposed Sale	3.54	3,935	13,910		Jul 09 04:48 PM
AUERBACH ALAN H	Officer	Jul 09 '25	Proposed Sale	3.54	21,580	76,285		Jul 09 04:36 PM
HUNT DOUGLAS M	Officer	Jul 09 '25	Proposed Sale	3.54	3,443	12,171		Jul 09 04:27 PM
AUERBACH ALAN H	Officer	Jul 08 '25	Proposed Sale	3.53	25,592	90,424		Jul 08 04:41 PM
NOUGUES MAXIMO F	Officer	Jul 08 '25	Proposed Sale	3.53	5,587	19,741		Jul 08 04:39 PM
HUNT DOUGLAS M	Officer	Jul 08 '25	Proposed Sale	3.53	4,374	15,455		Jul 08 04:29 PM

Open in Screener

KURA

Kura Oncology Inc

Jun 15 • 04:00PM ET

9.54

+0.49 5.41 %

Healthcare • Biotechnology • USA • Small • NASD

KURA Kura Oncology Inc daily Stock Chart

Peers: RCUS IDYA TNGX NUVL CGON KYMR RYTM BMRN INCY KRYS

| Held by: XBI VTI IWM VXF IWN IBB SCHA VTWO FESM VHT

Index	RUT	P/E	-	EPS (ttm)	-3.35	Insider Own	3.22%	Shs Outstand	88.76M	Perf Week	11.45%
Market Cap	846.91M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	-2.54%	Shs Float	85.91M	Perf Month	-2.05%
Enterprise Value	290.36M	PEG	-	EPS next Q	-0.90	Inst Own	94.77%	Short Float	15.82%	Perf Quarter	9.28%
Income	-294.57M	P/S	11.82	EPS this Y	-11.47%	Inst Trans	-1.74%	Short Ratio	8.31	Perf Half Y	-8.80%
Sales	71.64M	P/B	7.85	EPS next Y	25.13%	ROA	-42.19%	Short Interest	13.59M	Perf YTD	-8.18%
Book/sh	1.22	P/C	1.46	EPS next 5Y	14.34%	ROE	-124.74%	52W High	12.49 -23.62%	Perf Year	48.14%
Cash/sh	6.54	P/FCF	-	EPS past 3/5Y	-16.16% -13.48%	ROIC	-225.08%	52W Low	5.45 75.05%	Perf 3Y	-12.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	97.96%	Volatility	5.49% 6.54%	Perf 5Y	-57.60%
Dividend TTM	-	EV/Sales	4.05	EPS Y/Y TTM	-60.20%	Oper. Margin	-443.54%	ATR (14)	0.55	Perf 10Y	243.17%
Dividend Ex-Date	-	Quick Ratio	6.14	Sales Y/Y TTM	5.37%	Profit Margin	-411.19%	RSI (14)	53.73	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	6.15	EPS Q/Q	-25.97%	SMA20	0.76%	Beta	0.39	Target Price	31.17
Payout	-	Debt/Eq	0.22	Sales Q/Q	29.47%	SMA50	2.68%	Rel Volume	1.03	Prev Close	9.05
Employees	260	LT Debt/Eq	0.21	Earnings	May 12 AMC	SMA200	2.12%	Avg Volume	1.64M	Price	9.54
IPO	Sep 16, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.54% -29.67%	Trades		Volume	1,680,636	Change	5.41%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-26	Initiated	Lake Street	Buy	$23
Sep-04-25	Initiated	Guggenheim	Neutral
Feb-06-25	Downgrade	BTIG Research	Buy → Neutral
Oct-24-24	Initiated	UBS	Buy	$27
Oct-14-24	Downgrade	Stifel	Buy → Hold	$26 → $19
Dec-22-23	Initiated	Mizuho	Buy	$26
Aug-11-23	Initiated	BofA Securities	Buy	$31
Jul-27-23	Initiated	Scotiabank	Sector Perform	$10.50
May-17-23	Initiated	BTIG Research	Buy	$31
Jan-31-23	Initiated	Stifel	Buy	$25
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight	$30
Feb-15-22	Initiated	Jefferies	Buy	$35
May-05-21	Resumed	Credit Suisse	Outperform	$42
Apr-26-21	Resumed	Credit Suisse	Outperform	$42
Dec-07-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Dec-03-20	Initiated	Stifel	Buy	$45
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform	$27
May-05-20	Initiated	Barclays	Overweight	$24
Jul-18-19	Initiated	Deutsche Bank	Buy	$28

Show Previous Ratings

Jun-11-26 08:02AM	Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML (GlobeNewswire)
Jun-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 06:53AM	Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy (GlobeNewswire)
Jun-02-26 08:32AM	Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML (GlobeNewswire)
May-26-26 06:02AM	Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors (GlobeNewswire) -7.47%
04:02PM	Loading…
May-19-26 04:02PM	Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit (GlobeNewswire) +15.40%
May-13-26 08:30AM	Kura Oncology, Inc. Q1 2026 Earnings Call Summary (Moby)
01:02AM	Kura Oncology Inc (KURA) Q1 2026 Earnings Call Highlights: Strong KOMZIFTI Launch Amid Rising ... (GuruFocus.com)
May-12-26 04:10PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press)
04:02PM	Kura Oncology Reports First Quarter 2026 Financial Results (GlobeNewswire)
09:40AM	Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress (GlobeNewswire)
May-06-26 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire)
May-05-26 07:30AM	Kura Oncology to Report First Quarter 2026 Financial Results (GlobeNewswire)
May-04-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.47%
Apr-17-26 06:00AM	Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib (GlobeNewswire) +8.28%
07:30AM	Loading…
Apr-09-26 07:30AM	Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 (GlobeNewswire)
Apr-03-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.29%
Mar-05-26 09:07PM	Kura Oncology Q4 Earnings Call Highlights (MarketBeat)
02:01PM	Kura Oncology Inc (KURA) Q4 2025 Earnings Call Highlights: KOMZIFTI Launch Boosts Revenue Amid ... (GuruFocus.com)
12:36PM	Kura Oncology, Inc. Q4 2025 Earnings Call Summary (Moby)
07:40AM	Kura Oncology (KURA) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
06:47AM	Kura Oncology: Q4 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-26-26 07:30AM	Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-19-26 10:00AM	Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline (Zacks)
Feb-18-26 10:00AM	Earnings Preview: Kura Oncology (KURA) Q4 Earnings Expected to Decline (Zacks)
Feb-12-26 04:04PM	1 Under-$10 Stock Set to Surge as Much as 850% in 2026 (Barchart)
Feb-06-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.81%
09:36AM	Loading…
Feb-02-26 09:36AM	Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion (Insider Monkey)
Jan-21-26 04:51AM	New Strong Sell Stocks for January 21st (Zacks)
Jan-14-26 09:16AM	Kura Oncology price target lowered to $20 from $25 at Leerink (TipRanks)
Jan-11-26 05:00PM	Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones (GlobeNewswire)
Jan-05-26 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.69%
Dec-23-25 12:52AM	Jim Cramer Calls Kura Speculative But Says "It's One of the Stronger Ones I've Seen in a Very Long Time" (Insider Monkey)
Dec-21-25 10:26AM	Jim Cramer Discusses Kura Oncology as a Speculative Bet (Insider Monkey)
Dec-18-25 07:58PM	Lightning Round: Don't get involved in any 'year of magical investing' stock: Jim Cramer (CNBC TV)
Dec-15-25 11:10PM	Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval (Insider Monkey)
Dec-08-25 10:30AM	Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML (GlobeNewswire)
Dec-04-25 12:20PM	Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (PR Newswire)
Dec-03-25 08:32AM	Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia (GlobeNewswire) +7.55%
Dec-02-25 08:02AM	First U.S. Commercial Sale of KOMZIFTI Triggers $135 Million Milestone Payment to Kura Oncology Under Collaboration and License Agreement with Kyowa Kirin (GlobeNewswire)
Nov-25-25 05:16PM	KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML) (GlobeNewswire)
Nov-14-25 07:15AM	Kura and Kyowa Kirin secure FDA go-ahead for targeted leukaemia therapy (Pharmaceutical Technology)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 10:51AM	Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia (GlobeNewswire)
Nov-12-25 04:05PM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Nov-07-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-04-25 04:03PM	Kura Oncology Inc (KURA) Q3 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses (GuruFocus.com)
07:45AM	Kura Oncology (KURA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:50AM	Kura Oncology: Q3 Earnings Snapshot (Associated Press Finance)
06:31AM	Kura Oncology Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 04:02PM	Kura Oncology Receives Second $30 Million Development Milestone Payment in AML Menin Inhibitor Program With Kyowa Kirin (GlobeNewswire)
09:14AM	Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting (GlobeNewswire)
07:50AM	What To Expect From Kura Oncology Inc (KURA) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 04:01PM	Kura Oncology to Report Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-24-25 07:02AM	Kura Oncology Receives $30 Million Development Milestone Payment in Ziftomenib AML Program with Kyowa Kirin (GlobeNewswire) +6.59%
Oct-18-25 03:23AM	Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Oct-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:01AM	Kura Oncology and Kyowa Kirin Launch Clinical Trial Evaluating Dual Inhibition of NPM1 and FLT3 Mutations in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-29-25 04:01PM	Kura Oncology and Kyowa Kirin Announce First Patient Dosed in Pivotal Phase 3 KOMET-017 Trial of Ziftomenib for Frontline Acute Myeloid Leukemia (AML) (GlobeNewswire)
Sep-25-25 05:18PM	Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology (GlobeNewswire) +8.25%
Sep-24-25 07:30AM	Kura Oncology to Participate in Upcoming Investor Conference (GlobeNewswire)
Sep-16-25 04:01PM	Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types (GlobeNewswire)
Sep-08-25 12:30AM	LifeSci Capital Maintains Buy Rating on Kura Oncology (KURA) (Insider Monkey)
Sep-05-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 08:02AM	Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program (GlobeNewswire) +6.04%
Aug-28-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -7.05%
05:16PM	Kura Oncology: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-06-25 07:00AM	OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee (GlobeNewswire) -5.19%
Aug-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-31-25 07:30AM	Kura Oncology to Report Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-03-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-12-25 08:48AM	Is the Options Market Predicting a Spike in Kura Oncology Stock? (Zacks)
07:30AM	Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress (GlobeNewswire)
Jun-10-25 08:08PM	Lightning Round: 'Wait and see situation' with Papa John's, says Jim Cramer (CNBC TV)
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 06:00PM	Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting (GlobeNewswire) +10.72%
Jun-01-25 07:00PM	Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML (GlobeNewswire)
May-22-25 05:30PM	Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire) -9.62%
May-20-25 07:30AM	Kura Oncology to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
May-14-25 10:00AM	Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress (GlobeNewswire)
May-06-25 07:30AM	Kura Oncology to Participate in Bank of America Securities Healthcare Conference (GlobeNewswire) -13.84%
May-02-25 10:51AM	Q1 2025 Kura Oncology Inc Earnings Call (Thomson Reuters StreetEvents)
07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
03:17AM	Kura Oncology Inc (KURA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Costs (GuruFocus.com)
May-01-25 08:48PM	Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:26PM	Kura Oncology: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Kura Oncology Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-29-25 05:27AM	Kura doses first subjects in trial of ziftomenib for advanced GIST (Clinical Trials Arena)
Apr-28-25 07:30AM	Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST (GlobeNewswire)
Apr-24-25 07:30AM	Kura Oncology to Report First Quarter 2025 Financial Results (GlobeNewswire)
Apr-08-25 07:30AM	Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 07:30AM	Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Ph.D.Dr. Troy Edward Wilson J.D.

Chief Operating OfficerMs. Kathleen Ford

M.S.Mr. Brian T. Powl M.B.A.

Senior Vice President of Finance & AccountingMr. Thomas Doyle

Chief Scientific OfficerDr. Francis J. Burrows Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Powl Brian T.	Chief Commercial Officer	May 21 '26	Sale	11.00	10,000	110,000	173,614	May 22 04:05 PM
BRIAN POWL	Officer	May 21 '26	Proposed Sale	10.34	10,000	103,400		May 21 04:31 PM
Powl Brian T.	Chief Commercial Officer	May 19 '26	Sale	9.21	339	3,122	183,614	May 20 04:05 PM
FORD KATHLEEN	Chief Operating Officer	May 19 '26	Sale	9.08	2,257	20,483	153,560	May 20 04:05 PM
Bair Teresa Brophy	Chief Legal Officer	May 18 '26	Sale	9.38	2,256	21,160	226,931	May 20 04:05 PM
KATHLEEN FORD	Officer	May 19 '26	Proposed Sale	9.20	2,257	20,764		May 19 04:39 PM
BRIAN POWL	Officer	May 19 '26	Proposed Sale	9.20	339	3,119		May 19 04:37 PM
TERESA BAIR	Officer	May 18 '26	Proposed Sale	9.22	2,256	20,800		May 18 04:31 PM
WILSON TROY EDWARD	President and CEO	Mar 23 '26	Option Exercise	6.15	6,103	37,533	435,456	Mar 25 09:00 AM
Malley Thomas	Director	Mar 18 '26	Option Exercise	3.12	10,000	31,200	10,000	Mar 20 09:00 AM
Powl Brian T.	Chief Commercial Officer	Jan 27 '26	Sale	8.46	6,414	54,266	183,275	Jan 27 09:35 PM
FORD KATHLEEN	Chief Operating Officer	Jan 27 '26	Sale	8.46	1,813	15,339	153,560	Jan 27 09:35 PM
Leoni Mollie	Chief Medical Officer	Jan 27 '26	Sale	8.46	8,180	69,209	267,274	Jan 27 09:35 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Jan 27 '26	Sale	8.46	7,142	60,426	145,167	Jan 27 09:35 PM
Burrows Francis	Chief Scientific Officer	Jan 27 '26	Sale	8.46	1,311	11,092	32,424	Jan 27 09:35 PM
Bair Teresa Brophy	Chief Legal Officer	Jan 27 '26	Sale	8.46	11,208	94,828	226,931	Jan 27 09:35 PM
BAIR TERESA BROPHY	Officer	Jan 27 '26	Proposed Sale	8.47	11,208	94,932		Jan 27 09:30 PM
POWL BRIAN T	Officer	Jan 27 '26	Proposed Sale	8.47	6,414	54,327		Jan 27 09:30 PM
FORD KATHLEEN	Officer	Jan 27 '26	Proposed Sale	8.47	1,813	15,356		Jan 27 09:30 PM
LEONI MOLLIE	Officer	Jan 27 '26	Proposed Sale	8.47	8,180	69,285		Jan 27 09:30 PM
BURROWS FRANCIS	Officer	Jan 27 '26	Proposed Sale	8.47	1,311	11,104		Jan 27 09:30 PM
DOYLE THOMAS JAMES	Officer	Jan 27 '26	Proposed Sale	8.47	7,142	60,493		Jan 27 09:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Option Exercise	4.80	35,000	168,000	57,461	Dec 19 04:30 PM
Burrows Francis	Chief Scientific Officer	Dec 18 '25	Sale	9.78	23,726	231,931	33,735	Dec 19 04:30 PM
FRANCIS J BURROWS	Officer	Dec 18 '25	Proposed Sale	9.78	23,726	231,934		Dec 18 04:07 PM
Hasnain Faheem	Director	Dec 09 '25	Option Exercise	3.12	10,000	31,200	33,983	Dec 10 04:05 PM
Hasnain Faheem	Director	Dec 09 '25	Sale	10.98	10,000	109,764	23,983	Dec 10 04:05 PM
FAHEEM HASNAIN	Director	Dec 09 '25	Proposed Sale	11.64	10,000	116,400		Dec 09 04:23 PM
Bair Teresa Brophy	Chief Legal Officer	Nov 14 '25	Sale	11.18	8,804	98,401	188,139	Nov 14 08:00 PM
Powl Brian T.	Chief Commercial Officer	Nov 14 '25	Sale	11.18	8,887	99,329	139,689	Nov 14 08:00 PM
Leoni Mollie	Chief Medical Officer	Nov 14 '25	Sale	11.18	15,485	173,074	225,454	Nov 14 08:00 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Nov 14 '25	Sale	11.18	4,539	50,732	130,257	Nov 14 08:00 PM
FORD KATHLEEN	Officer	Nov 14 '25	Proposed Sale	10.68	6,902	73,713		Nov 14 08:00 PM
DOYLE THOMAS JAMES	Officer	Nov 14 '25	Proposed Sale	10.68	4,539	48,477		Nov 14 08:00 PM
FORD KATHLEEN	Chief Operating Officer	Nov 14 '25	Sale	11.18	6,902	77,143	105,373	Nov 14 08:00 PM
LEONI MOLLIE	Officer	Nov 14 '25	Proposed Sale	10.68	15,485	165,380		Nov 14 08:00 PM
POWL BRIAN T	Officer	Nov 14 '25	Proposed Sale	10.68	8,887	94,913		Nov 14 08:00 PM
BAIR TERESA BROPHY	Officer	Nov 14 '25	Proposed Sale	10.68	8,804	94,027		Nov 14 08:00 PM
WILSON TROY EDWARD	Officer	Sep 29 '25	Proposed Sale	9.05	36,615	331,366		Sep 29 07:50 PM
LEONI MOLLIE	Officer	Sep 29 '25	Proposed Sale	9.05	12,314	111,442		Sep 29 07:50 PM
POWL BRIAN T	Officer	Sep 29 '25	Proposed Sale	9.05	8,891	80,464		Sep 29 07:50 PM
BAIR TERESA BROPHY	Officer	Sep 29 '25	Proposed Sale	9.05	8,805	79,685		Sep 29 07:50 PM
DOYLE THOMAS JAMES	Officer	Sep 29 '25	Proposed Sale	9.05	4,541	41,096		Sep 29 07:50 PM
FORD KATHLEEN	Officer	Sep 29 '25	Proposed Sale	9.05	6,892	62,373		Sep 29 07:50 PM
Powl Brian T.	Chief Commercial Officer	Sep 29 '25	Sale	8.94	8,891	79,505	99,676	Sep 29 07:30 PM
Bair Teresa Brophy	Chief Legal Officer	Sep 29 '25	Sale	8.94	8,805	78,736	148,043	Sep 29 07:30 PM
FORD KATHLEEN	Chief Operating Officer	Sep 29 '25	Sale	8.94	6,892	61,630	63,375	Sep 29 07:30 PM
Leoni Mollie	Chief Medical Officer	Sep 29 '25	Sale	8.94	12,314	110,114	158,439	Sep 29 07:30 PM
WILSON TROY EDWARD	President and CEO	Sep 29 '25	Sale	8.94	36,615	327,419	246,853	Sep 29 07:30 PM
DOYLE THOMAS JAMES	SVP, Finance & Accounting	Sep 29 '25	Sale	8.94	4,541	40,607	109,829	Sep 29 07:30 PM
WILSON TROY EDWARD	President & CEO	Sep 08 '25	Buy	8.20	50,000	410,145	100,968	Sep 09 04:28 PM
WILSON TROY EDWARD	President and CEO	Aug 12 '25	Buy	5.85	36,506	213,578	37,474	Aug 14 04:05 PM
WILSON TROY EDWARD	President and CEO	Aug 13 '25	Buy	6.64	13,494	89,623	50,968	Aug 14 04:05 PM

Open in Screener

RNA

Atrium Therapeutics Inc

Jun 15 • 04:00PM ET

12.75

+0.38 3.07 %

Healthcare • Biotechnology • USA • Micro • NASD

RNA Atrium Therapeutics Inc daily Stock Chart

Peers: KPTI OABI CAMP CNTX HUMA TENX TNXP UNCY WHWK MIST

| Held by: VTI IWM VB VXF IWO JSML SCHA VTWO VBR VBK

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.22%	Shs Outstand	17.11M	Perf Week	10.39%
Market Cap	218.10M	Forward P/E	-	EPS next Y	-5.49	Insider Trans	-60.82%	Shs Float	17.07M	Perf Month	-3.92%
Enterprise Value	-47.07M	PEG	-	EPS next Q	-1.42	Inst Own	86.52%	Short Float	21.40%	Perf Quarter	-7.54%
Income	-	P/S	-	EPS this Y	-17.19%	Inst Trans	13.95%	Short Ratio	9.66	Perf Half Y	-
Sales	-	P/B	0.93	EPS next Y	-4.57%	ROA	-	Short Interest	3.65M	Perf YTD	-13.56%
Book/sh	13.69	P/C	0.81	EPS next 5Y	-9.55%	ROE	-	52W High	16.77 -23.97%	Perf Year	-
Cash/sh	15.66	P/FCF	-	EPS past 3/5Y	-178.43% -	ROIC	-	52W Low	11.40 11.81%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	38.09% -	Gross Margin	-	Volatility	4.59% 4.34%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	0.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.86	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	13.04	EPS Q/Q	-	SMA20	1.63%	Beta	-	Target Price	40.67
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-2.46%	Rel Volume	0.69	Prev Close	12.37
Employees	-	LT Debt/Eq	0.00	Earnings	May 14 AMC	SMA200	-4.72%	Avg Volume	378.31K	Price	12.75
IPO	Jun 12, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	7.62% 881.75%	Trades		Volume	261,506	Change	3.07%

Date	Action	Analyst	Rating Change	Price Target Change
May-15-26	Initiated	Leerink Partners	Outperform	$25
Mar-11-26	Initiated	Wells Fargo	Overweight	$25
Sep-17-25	Initiated	Roth Capital	Buy	$62
Jul-10-25	Resumed	Goldman	Buy	$55
Jun-24-25	Initiated	Bernstein	Outperform	$50
Jun-17-25	Initiated	Wolfe Research	Outperform	$55
Jun-11-25	Initiated	Raymond James	Strong Buy	$65
Mar-13-25	Initiated	Citigroup	Buy	$70
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$72
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$70
Dec-20-24	Initiated	H.C. Wainwright	Buy	$72
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$67
Sep-24-24	Initiated	Goldman	Buy	$59
Aug-28-24	Initiated	Barclays	Overweight	$63
May-03-24	Initiated	BofA Securities	Buy	$40
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight	$60
May-22-23	Upgrade	Evercore ISI	In-line → Outperform	$20
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line	$20
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$29
Jul-12-22	Initiated	Raymond James	Strong Buy	$29

Show Previous Ratings

May-14-26 04:40PM	Atrium Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
Apr-23-26 08:00AM	Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration (PR Newswire)
Apr-20-26 10:46PM	Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.38%
Mar-19-26 04:00AM	Novartis acquisition spin-off pioneers RNA therapeutics for the heart (Pharma Voice)
Mar-17-26 08:09AM	Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal (GuruFocus.com)
04:05PM	Loading…
Feb-27-26 04:05PM	Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger (Insider Monkey)
09:19AM	Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies (PR Newswire)
07:58AM	Atrium spins out of Avidity, aiming to target rare heart diseases with RNA (BioPharma Dive)
Feb-26-26 04:02PM	Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Feb-23-26 08:00AM	Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders (PR Newswire)
Feb-18-26 05:00PM	The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 (PR Newswire)
Feb-04-26 09:32AM	Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales (Zacks)
Feb-02-26 09:44PM	Avidity Biosciences Announces Expected Record Date for Spin-Off (PR Newswire)
Jan-22-26 07:10AM	Immunocore (IMCR) Soars 5.9%: Is Further Upside Left in the Stock? (Zacks)
Jan-13-26 11:43AM	JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals (Pharmaceutical Technology)
08:57AM	Loading…
Dec-09-25 08:57AM	Novartis Drops $1.7 Billion on AI Allergy Breakthrough (GuruFocus.com)
Dec-04-25 01:59PM	Avidity Biosciences, Inc. (RNA): A Bull Case Theory (Insider Monkey)
Dec-01-25 06:59PM	Halper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch)
09:31AM	US healthcare group Abbott bets on cancer screening technology in $23bn deal (Financial Times)
01:51AM	Novartis Expects Steady Sales Growth Through 2030 (The Wall Street Journal)
Nov-10-25 05:25PM	Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
Nov-07-25 04:34PM	Halper Sadeh LLC Encourages WTRG, PLYM, RNA Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-04-25 10:00AM	Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Nov-03-25 01:34AM	Avidity Biosciences (RNA) Soars 42% on $12-Billion Novartis Merger (Insider Monkey)
Oct-31-25 09:44AM	Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think) (Motley Fool)
12:23PM	Loading…
Oct-30-25 12:23PM	Halper Sadeh LLC Encourages RNA, JAMF, AWK Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-29-25 02:49PM	Fresh List of Stocks With Short Squeeze Potential (Schaeffer's Research)
Oct-28-25 10:14AM	Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition (Zacks)
09:42AM	Warner Bros. Discovery upgraded, F5 downgraded: Wall Street's top analyst calls (The Fly)
09:17AM	Avidity Biosciences (RNA) Moves 42.4% Higher: Will This Strength Last? (Zacks)
06:26AM	Novartis Expects to Ride Out Patent Losses With Sales, Profit Growth Ahead (The Wall Street Journal)
06:11AM	S&P Futures Muted After Record Rally, FOMC Meeting and Earnings in Focus (Barchart)
05:24AM	Avidity Biosciences (RNA) Soars to All-Time High on Looming $12-Billion Merger with Novartis (Insider Monkey)
04:00AM	Novartis $12B Avidity deal shows a willingness to take big swings in neuroscience (Pharma Voice)
Oct-27-25 05:12PM	Why Avidity Biosciences Stock Blasted 42% Higher Today (Motley Fool)
05:09PM	Health Care Roundup: Market Talk (The Wall Street Journal)
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
04:51PM	Stocks to Watch Monday: Amazon, Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
04:34PM	These Stocks Are Moving the Most Today: Qualcomm, MP Materials, USA Rare Earth, Tesla, Avidity, Newmont, Microsoft, and More (Barrons.com)
01:01PM	HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
12:55PM	Novartis Just Dropped $12 Billion on a Biotech Moonshot--Here's What Investors Need to Know (GuruFocus.com)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
11:16AM	Novartis Avidity Deal Is a Green Light for Biotech Rally (Barrons.com)
09:38AM	Stocks to Watch Monday: Nvidia, Novartis, Keurig Dr Pepper (The Wall Street Journal)
09:24AM	Novartis to buy Avidity for $12B, Keurig Dr Pepper raises outlook (Yahoo Finance Video)
08:25AM	5 Things to Know Before the Stock Market Opens (Investopedia)
08:19AM	USA Rare Earth, Iren, Novartis, Softbank: Trending Stocks (Yahoo Finance Video)
06:49AM	Fed, Tech Earnings and Trump-Xi Talks. Why One Matters Most for Markets. (Barrons.com)
06:08AM	MP Materials slumps, Avidity Biosciences surges and other movers (MarketWatch)
05:51AM	Novartis agrees to buy Avidity Biosciences for $12bn (Pharmaceutical Technology)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:59AM	Stock Market Today: Dow set for 200-point rise, S&P 500 and Nasdaq to pop after weekend talks between U.S. and China (MarketWatch)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
04:39AM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
Oct-26-25 05:33PM	Novartis Agrees to Acquire Avidity Biosciences for $12 Billion (The Wall Street Journal)
04:25PM	Novartis acquiring US firm Avidity Biosciences for $12 bn (AFP)
03:43PM	Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion (USA TODAY)
03:29PM	Novartis Deal Values Avidity Biosciences At $12 Billion (Barrons.com)
01:07PM	Avidity Biosciences Enters into Agreement to be Acquired by Novartis AG (PR Newswire)
11:07AM	Novartis to acquire Avidity in $12B bet on RNA drugs for neuromuscular disease (BioPharma Dive)
Oct-16-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conference (PR Newswire)
Oct-13-25 09:00AM	Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire)
07:31AM	What Makes Avidity Biosciences (RNA) an Investment Choice? (Insider Monkey)
Oct-06-25 09:00AM	Avidity Biosciences to Present Data from EXPLORE44 Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire)
Sep-24-25 04:06AM	Avidity Biosciences (RNA) Announces Positive One-Year Data For its, Del-Zota (Insider Monkey)
Sep-17-25 09:33AM	Netflix upgraded, Five Below initiated: Wall Street's top analyst calls (The Fly)
Sep-15-25 04:01PM	Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Sep-13-25 12:01PM	Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating (Insider Monkey)
Sep-12-25 06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-10-25 04:01PM	Avidity Biosciences Announces Proposed Public Offering of Common Stock (PR Newswire)
07:00AM	Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44 and EXPLORE44-OLE Phase 1/2 Trial in People Living with DMD44 (PR Newswire)
12:59AM	Cantor Fitzgerald Reiterates a Buy Rating on Avidity Biosciences (RNA) (Insider Monkey)
Aug-27-25 09:00AM	Avidity Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-25 02:23PM	RNA Stock Moves More Than 30% in a Week: What's Driving This Rally? (Zacks)
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-13-25 08:15AM	Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-12-25 05:15PM	Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-07-25 05:10PM	Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire)
10:19AM	Avidity (RNA) Gets 26% Jump on Potential Takeover (Insider Monkey)
Aug-06-25 05:10PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
12:47PM	Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal (Investor's Business Daily)
12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com)
11:41AM	Novartis weighs deal for biotech Avidity Biosciences, FT reports (Reuters)
Jul-28-25 09:39AM	Facioscapulohumeral Muscular Dystrophy Pipeline Market Insight Report 2025 \| In-depth Analysis of 10+ Companies and 12+ Pipeline Drugs (GlobeNewswire)
09:00AM	Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission (PR Newswire)
Jul-26-25 11:03AM	Avidity (RNA) Jumps 9.2% on Drug Candidate's Breakthrough Therapy Designation (Insider Monkey)
Jul-23-25 09:00AM	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping (PR Newswire)
Jul-13-25 06:15AM	Raymond James Predicts Up to ~760% Surge for These 2 Strong Buy Stocks (TipRanks)
Jun-11-25 08:03PM	Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James (Insider Monkey)
09:45AM	Raymond James bullish on biotech firms on favorable valuation (Investing.com)
09:00AM	Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress (PR Newswire)
Jun-10-25 09:25AM	Avidity Biosciences price target raised to $75 from $65 at Chardan (TipRanks)
Jun-09-25 02:04PM	Avidity Biosciences Touts Encouraging Functional Gains And Biomarker Reductions In Rare Muscular Weakness Disease Trial (Benzinga)

Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

PresidentMs. Kathleen P. Gallagher

Chief Financial OfficerMr. Brendan Winslow

Chief Scientific OfficerDr. Husam Younis

Chief Corporate Affairs OfficerMs. Stephanie Kenney

M.D.Dr. Steven George Hughes M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hughes Steven George	Chief Medical Officer	Jan 21 '26	Sale	72.45	4,895	354,643	31,599	Jan 23 05:34 PM
Boyce Sarah	President and CEO	Jan 21 '26	Sale	72.45	14,387	1,042,338	269,007	Jan 23 05:34 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 21 '26	Sale	72.45	6,534	473,388	85,093	Jan 23 05:33 PM
MacLean Michael F	Chief Financial Officer	Jan 21 '26	Sale	72.45	4,542	329,068	59,290	Jan 23 05:33 PM
LEVIN ARTHUR A	Director	Jan 21 '26	Sale	72.45	1,758	127,367	16,562	Jan 23 05:33 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 21 '26	Sale	72.45	2,929	212,206	113,938	Jan 23 05:33 PM
Boyce Sarah	President and CEO	Jan 07 '26	Sale	72.23	8,576	619,444	283,394	Jan 09 05:13 PM
Calderaro Charles III	Chief Technical Officer	Jan 07 '26	Sale	72.23	3,727	269,201	49,797	Jan 09 05:13 PM
McCarthy Teresa	Chief Human Resources Officer	Jan 07 '26	Sale	72.23	1,965	141,932	116,867	Jan 09 05:13 PM
Moriarty John B	Chief Legal Officer	Jan 07 '26	Sale	72.23	2,374	171,474	74,557	Jan 09 05:12 PM
MacLean Michael F	Chief Financial Officer	Jan 07 '26	Sale	72.23	1,974	142,582	63,832	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Jan 07 '26	Sale	72.23	2,373	171,402	36,494	Jan 09 05:12 PM
Flanagan W. Michael	Chief Scientific Officer	Jan 07 '26	Sale	72.23	2,373	171,402	91,627	Jan 09 05:12 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Option Exercise	10.16	2,209	22,443	41,076	Oct 24 04:56 PM
Hughes Steven George	Chief Medical Officer	Oct 22 '25	Sale	47.54	2,209	105,015	38,867	Oct 24 04:56 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Option Exercise	22.34	20,000	446,800	117,130	Oct 17 04:27 PM
McCarthy Teresa	Chief Human Resources Officer	Oct 15 '25	Sale	50.15	20,000	1,003,058	97,130	Oct 17 04:27 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Option Exercise	9.05	6,562	59,386	61,562	Oct 07 04:11 PM
Mosbrooker Eric	Chief Commercial Officer	Oct 03 '25	Sale	45.38	6,562	297,771	55,000	Oct 07 04:11 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Sep 23 04:57 PM
Hughes Steven George	Chief Medical Officer	Sep 22 '25	Sale	40.58	2,208	89,601	38,867	Sep 23 04:57 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Option Exercise	22.34	15,000	335,100	112,130	Sep 17 04:03 PM
McCarthy Teresa	Chief Human Resources Officer	Sep 15 '25	Sale	41.41	15,000	621,142	97,130	Sep 17 04:03 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Option Exercise	6.57	1,542	10,131	40,409	Sep 17 04:02 PM
Hughes Steven George	Chief Medical Officer	Sep 15 '25	Sale	45.41	1,542	70,022	38,867	Sep 17 04:02 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Option Exercise	14.22	20,000	284,400	100,195	Sep 12 04:07 PM
Flanagan W. Michael	Chief Scientific Officer	Sep 11 '25	Sale	38.94	20,000	778,702	80,195	Sep 12 04:07 PM
WILLIAM MICHAEL FLANAGAN	Officer	Sep 11 '25	Proposed Sale	46.40	20,000	928,000		Sep 11 04:24 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Option Exercise	12.48	14,500	180,960	83,925	Sep 09 05:53 PM
WILSON TROY EDWARD	Director	Sep 05 '25	Sale	50.00	29,500	1,475,000	54,425	Sep 09 05:53 PM
Boyce Sarah	President and CEO	Sep 05 '25	Option Exercise	1.24	50,000	62,000	355,871	Sep 05 06:56 PM
Boyce Sarah	President and CEO	Sep 05 '25	Sale	49.95	50,000	2,497,435	305,871	Sep 05 06:56 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Option Exercise	9.05	6,563	59,395	61,563	Sep 05 06:32 PM
Mosbrooker Eric	Chief Commercial Officer	Sep 03 '25	Sale	47.07	6,563	308,936	55,000	Sep 05 06:32 PM
SARAH BOYCE	Director	Sep 05 '25	Proposed Sale	48.47	50,000	2,423,500		Sep 05 04:25 PM
WILSON TROY EDWARD	Chairman	Sep 05 '25	Proposed Sale	50.00	95,052	4,752,600		Sep 05 04:10 PM
ERIC MOSBROOKER	Officer	Sep 03 '25	Proposed Sale	47.23	19,688	929,864		Sep 03 04:31 PM
Gallagher Kathleen P.	Chief Program Officer	Sep 02 '25	Sale	47.42	188	8,915	50,204	Sep 02 08:30 PM
Boyce Sarah	President and CEO	Aug 28 '25	Option Exercise	1.24	25,000	31,000	330,871	Aug 29 04:28 PM
Boyce Sarah	President and CEO	Aug 28 '25	Sale	49.39	25,000	1,234,700	305,871	Aug 29 04:28 PM
SARAH BOYCE	Director	Aug 28 '25	Proposed Sale	47.82	25,000	1,195,500		Aug 28 04:21 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Option Exercise	10.16	2,208	22,433	41,075	Aug 22 05:20 PM
Hughes Steven George	Chief Medical Officer	Aug 22 '25	Sale	46.40	2,208	102,462	38,867	Aug 22 05:20 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Option Exercise	22.34	10,000	223,400	107,130	Aug 15 05:50 PM
McCarthy Teresa	Chief Human Resources Officer	Aug 15 '25	Sale	46.56	10,000	465,632	97,130	Aug 15 05:50 PM
TERESA MCCARTHY	Officer	Aug 15 '25	Proposed Sale	46.07	45,000	2,073,150		Aug 15 04:27 PM
MacLean Michael F	Chief Financial Officer	Aug 06 '25	Sale	42.73	30,914	1,320,844	65,806	Aug 15 04:09 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Option Exercise	6.57	1,542	10,131	40,409	Aug 15 04:07 PM
Hughes Steven George	Chief Medical Officer	Aug 13 '25	Sale	46.66	1,542	71,950	38,867	Aug 15 04:07 PM
STEVEN GEORGE HUGHES	Officer	Aug 13 '25	Proposed Sale	46.23	9,709	448,847		Aug 13 04:31 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Option Exercise	9.05	124,687	1,128,417	185,807	Aug 08 05:45 PM
Mosbrooker Eric	Chief Commercial Officer	Aug 06 '25	Sale	44.06	130,807	5,763,697	55,000	Aug 08 05:45 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Option Exercise	12.14	29,500	358,260	91,425	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	65,554	2,949,930	17,776	Aug 08 05:42 PM
WILSON TROY EDWARD	Director	Aug 06 '25	Sale	45.00	29,500	1,327,500	69,425	Aug 08 05:42 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Option Exercise	22.34	107,500	2,401,550	127,150	Aug 08 05:41 PM
LEVIN ARTHUR A	Director	Aug 06 '25	Sale	47.62	107,500	5,118,881	19,650	Aug 08 05:41 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Option Exercise	12.21	47,451	579,180	90,517	Aug 08 05:39 PM
Hughes Steven George	Chief Medical Officer	Aug 06 '25	Sale	42.74	81,434	3,480,269	38,867	Aug 08 05:39 PM
ERIC MOSBROOKER	Officer	Aug 06 '25	Proposed Sale	38.26	130,807	5,004,676		Aug 06 04:23 PM
STEVEN GEORGE HUGHES	Officer	Aug 06 '25	Proposed Sale	38.26	81,434	3,115,665		Aug 06 04:23 PM
ARTHUR LEVIN	Director	Aug 06 '25	Proposed Sale	38.26	107,500	4,112,950		Aug 06 04:23 PM
MICHAEL MACLEAN	Officer	Aug 06 '25	Proposed Sale	38.26	30,914	1,182,770		Aug 06 04:22 PM
WILSON TROY EDWARD	Chairman	Aug 06 '25	Proposed Sale	45.00	95,054	4,277,430		Aug 06 04:08 PM
Moriarty John B	Chief Legal Officer	Aug 04 '25	Sale	36.21	2,245	81,291	47,755	Aug 05 05:27 PM
Gallagher Kathleen P.	Chief Program Officer	Jun 17 '25	Sale	30.24	911	27,549	50,392	Jun 18 06:02 PM
KATHLEEN GALLAGHER	Officer	Jun 17 '25	Proposed Sale	29.80	911	27,148		Jun 17 04:19 PM

PBYI

Puma Biotechnology Inc

KURA

Kura Oncology Inc

RNA

Atrium Therapeutics Inc

Upgrade your Finviz experience